Olimestra (Olmesartan Medoxomil)

Olmesartan Medoxomil, the active ingredient in Olimestra, is an angiotensin II receptor blocker presented as a tablet for oral use. It treats hypertension and is indicated for use in adults who require blood pressure management. GNH USA supplies Olimestra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olimestra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olimestra is an angiotensin‑blocking agent used in the management of cardiovascular conditions that involve the renin‑angiotensin system.

- Hypertension: helps lower systolic and diastolic blood pressure to target levels. - Heart failure: used as part of combination therapy to improve cardiac output and reduce hospitalisation risk. - Diabetic nephropathy: slows progression of kidney damage by controlling blood pressure. - Post‑myocardial infarction: assists in long‑term blood‑pressure control to reduce strain on the healing heart. - Stroke prevention: contributes to secondary prevention by maintaining optimal blood pressure. - Chronic kidney disease: aids in preserving renal function through sustained blood‑pressure control.

Olimestra may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Nasal congestion - Diarrhoea - Cough

Serious or Rare Side Effects: - Angio‑edema involving the face, lips or tongue - Severe hypotension - Acute kidney injury - Hyperkalemia - Liver enzyme elevation - Allergic skin reactions such as Stevens‑Johnson syndrome

When prescribing Olimestra, clinicians should consider several safety aspects.

- Blood pressure monitoring: check baseline and periodic readings to avoid excessive fall. - Renal function assessment: evaluate creatinine and eGFR before initiation and during therapy. - Electrolyte surveillance: monitor serum potassium, especially if combined with potassium‑sparing agents. - Pregnancy contraindication: avoid use in pregnancy due to fetal toxicity. - Drug‑interaction review: assess concurrent medications that affect the renin‑angiotensin system. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Olimestra can interact with several medicines that influence blood pressure, renal function or electrolyte balance.

Major Interactions (Avoid): - Dual renin‑angiotensin blockade (e.g., ACE inhibitors, other ARBs): risk of severe hypotension, hyperkalaemia, renal impairment. - Potassium‑rich supplements or potassium‑sparing diuretics: may cause dangerous hyperkalaemia. - Aliskiren in diabetic patients: increased risk of renal dysfunction and hypotension.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can blunt antihypertensive effect and affect kidney function. - Diuretics (thiazides): may enhance hypotensive response. - Lithium: may increase lithium levels, risking toxicity. - Antacids containing aluminium or magnesium: may reduce olmesartan absorption. - Rifampicin: may lower olmesartan plasma concentrations.